KalVista Pharmaceuticals KALV
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
KalVista Pharmaceuticals (KALV) Business Model and Operations Summary
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Key Insights
KalVista Pharmaceuticals (KALV) Core Market Data and Business Metrics
Latest Closing Price
$15.39Market Cap
$669.17 MillionAverage Daily Volume
588,152 Shares52-Week Range
$7.30-$15.50Price-Earnings Ratio
-4.17Total Outstanding Shares
49.95 Million SharesCEO
Mr. Benjamin L. PalleikoTotal Employees
270Current Dividend
No dividendIPO Date
April 9, 2015SIC Description
Pharmaceutical PreparationsHeadquarters
55 Cambridge Parkway, Cambridge, MA, 02142